Sanofi-Aventis criticized on its future star drug
Posted by adminSanofi-Aventis could make a slam. According to information from La Tribune, the French Commission of transparency would render an opinion "poor" on the Multaq, a drug for heart problems. For a close case, "the Multaq nothing new on the market," reports the Economic Daily.
So the reimbursement by Social Security for this treatment is only 35%. And the product, which received the worst rating in terms of "improving the medical service rendered" and should be sold cheaper than similar treatments. Poor reward for fifteen years of research on this product.
Sanofi declined to comment, according to the newspaper, which said that the Commission's opinion is only "advisory" from the Economic Health Products, under the Ministry of Health.It is this body that negotiates with the laboratory conditions with the Social Security reimbursements.
Sanofi is one billion euros per year
However, Sanofi is quite a setback. Largely symbolic. For the pharmaceutical group is criticizing France. The Multaq had already been judged as not providing cost-effective.
If he agrees that France is not a huge market for the group to 29 billion euros of revenue, reputation could take a hit.
Counter the loss of patent
The French giant has bet big on this treatment, while many patents will soon expire.Natixis analysts have estimated that the contribution to turnover in the long term would be "significant": Courtesy of European marketing, which allows the group to receive an exclusive ten years, and that obtained United States (exclusive of five years), Sanofi-Aventis is expected to garner about one billion euros per year on average until 2019 with this future blockbuster.
Specifically, in 2019, the "turnover of 800 million euros in 2019 globally for the product, after peaking at 1.45 billion in 2015, before falling U.S. sales from 2016, then their disappearance, "say the strategists, calling the Multaq" relay major growth. "
For them, Multaq is "one of the four pillars to an increase in earnings per share by 2014, with Vacina, Lantus, and emerging countries, where the group leader.
ALSO READ:
"U.S. Green Light for Sanofi-Aventis
"United Kingdom: Multaq Sanofi-Aventis too expensive
"Sanofi-Aventis restructures its research